DK1005488T4 - Receptor som binder TRAIL - Google Patents

Receptor som binder TRAIL

Info

Publication number
DK1005488T4
DK1005488T4 DK98908474.4T DK98908474T DK1005488T4 DK 1005488 T4 DK1005488 T4 DK 1005488T4 DK 98908474 T DK98908474 T DK 98908474T DK 1005488 T4 DK1005488 T4 DK 1005488T4
Authority
DK
Denmark
Prior art keywords
trail
receptor
expression vectors
dna sequences
binds trail
Prior art date
Application number
DK98908474.4T
Other languages
English (en)
Other versions
DK1005488T3 (da
Inventor
Charles Rauch
Henning Dr Walczak
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27542220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1005488(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of DK1005488T3 publication Critical patent/DK1005488T3/da
Application granted granted Critical
Publication of DK1005488T4 publication Critical patent/DK1005488T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
DK98908474.4T 1997-02-13 1998-02-11 Receptor som binder TRAIL DK1005488T4 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US79986197A 1997-02-13 1997-02-13
US81525597A 1997-03-12 1997-03-12
US82953697A 1997-03-28 1997-03-28
US86985297A 1997-06-04 1997-06-04
US08/883,036 US6072047A (en) 1997-02-13 1997-06-26 Receptor that binds trail
PCT/US1998/002239 WO1998035986A1 (en) 1997-02-13 1998-02-11 Receptor that binds trail

Publications (2)

Publication Number Publication Date
DK1005488T3 DK1005488T3 (da) 2006-03-06
DK1005488T4 true DK1005488T4 (da) 2012-01-16

Family

ID=27542220

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98908474.4T DK1005488T4 (da) 1997-02-13 1998-02-11 Receptor som binder TRAIL

Country Status (13)

Country Link
US (3) US6072047A (da)
EP (2) EP1005488B9 (da)
JP (1) JP5031132B2 (da)
AT (1) ATE308561T1 (da)
AU (1) AU735686B2 (da)
CA (1) CA2279838A1 (da)
DE (1) DE69832178T3 (da)
DK (1) DK1005488T4 (da)
ES (1) ES2251767T5 (da)
HK (1) HK1029796A1 (da)
IL (2) IL131030A0 (da)
NZ (1) NZ336929A (da)
WO (1) WO1998035986A1 (da)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020160446A1 (en) * 2000-11-14 2002-10-31 Holtzman Douglas A. Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses
US6313269B1 (en) * 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
US20040136951A1 (en) * 1997-03-17 2004-07-15 Human Genome Sciences, Inc. Death domain containing receptor 5
US20050233958A1 (en) * 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
CA2644454A1 (en) 1997-03-17 1998-09-24 Human Genome Sciences, Inc. Death domain containing receptor 5
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
EP0981618B2 (en) * 1997-05-15 2011-08-24 Genentech, Inc. Anti-apo-2 antibody
JP2001514888A (ja) * 1997-08-15 2001-09-18 アイドゥン ファーマシューティカルズ， インコーポレイテッド Ｔｒａｉｌレセプター、これをコードする核酸、およびその使用方法
EP1012179A2 (en) * 1997-09-12 2000-06-28 Apotech R&D S.A. Cysteine rich receptors: trail
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
AU4561199A (en) * 1998-06-12 1999-12-30 Genentech Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
US6951738B2 (en) 1999-07-16 2005-10-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptors TR13 and TR14
EP1203024A4 (en) * 1999-07-16 2003-02-26 Human Genome Sciences Inc HUMAN TUMOR NECROSIS FACTOR RECEPTORS TR13 AND TR14
WO2001010908A1 (en) 1999-08-04 2001-02-15 Amgen Inc. Ntr3, a member of the tnf-receptor supergene family
MXPA02001264A (es) 1999-08-04 2002-07-22 Amgen Inc Fhm, nuevo miembro de la familia de supergenes de ligando de factor de necrosis tumoral.
US20030134788A1 (en) * 1999-08-12 2003-07-17 Baker Kevin P. Human tumor necrosis factor receptor TR16
WO2001012671A1 (en) * 1999-08-12 2001-02-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr16
ATE313634T1 (de) 1999-09-27 2006-01-15 Genentech Inc Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose
AU2006201322A1 (en) * 1999-09-27 2006-04-27 Genentech, Inc. Methods for making recombinant proteins using apoptosis inhibitors
ES2267593T3 (es) 2000-02-16 2007-03-16 Genentech, Inc. Anticuerpos anti-april y celulas hibridomas.
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) * 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
KR100436089B1 (ko) * 2000-07-06 2004-06-14 설대우 분비성 재조합 트라이머형의 트레일 단백질 생산을 위한 디엔에이 카세트, 테트라사이클린/독시사이클린-유도성아데노-관련 바이러스 벡터, 이 둘의 조합, 및 이들을이용한 유전자 치료
EP1303293B1 (en) 2000-07-27 2008-12-03 Genentech, Inc. Sequential administration of cpt-11 and apo-2l polypeptide
US20040005314A1 (en) * 2001-07-27 2004-01-08 Enrique Escandon Apo-2l receptor agonist and cpt-11 synergism
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
CA2426710A1 (en) * 2000-11-08 2002-10-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US20030139963A1 (en) * 2000-12-08 2003-07-24 Chickering D. Maxwell Decision theoretic approach to targeted solicitation by maximizing expected profit increases
US20020155109A1 (en) * 2001-04-20 2002-10-24 Lynch David H. Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
KR100932577B1 (ko) * 2001-05-18 2009-12-17 기린 홀딩스 가부시키가이샤 항 ｔｒａｉｌ-ｒ 항체
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
MXPA03010747A (es) * 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
EP2192130A1 (en) 2001-07-03 2010-06-02 Genentech, Inc. Human DR4 antibodies and uses thereof
WO2003013555A1 (en) * 2001-08-08 2003-02-20 Board Of Regents, The University Of Texas System Method for amplifying expression from a cell specific promoter
IL161051A0 (en) 2001-10-02 2004-08-31 Genentech Inc Apo-2 ligand variants and uses thereof
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
DK1450847T3 (da) 2001-11-13 2010-12-13 Genentech Inc Apo2-ligand/TRAIL-formuleringer og anvendelser deraf
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
WO2003054216A2 (en) * 2001-12-20 2003-07-03 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
EP2500032A1 (en) 2002-06-24 2012-09-19 Genentech, Inc. APO-2 ligand/trail variants and uses thereof
ES2327409T3 (es) * 2003-03-26 2009-10-29 Apogenix Gmbh Proteinas de fusion fc mejoradas.
KR20060132006A (ko) * 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
DK1774037T3 (da) * 2004-08-06 2011-08-15 Genentech Inc Analyser og fremgangsmåder, der anvender biomarkører
ZA200701614B (en) * 2004-08-06 2008-10-29 Genentech Inc Assays and methods using biomarkers
KR20070050950A (ko) * 2004-09-08 2007-05-16 제넨테크, 인크. 사멸 수용체 리간드 및 ｃｄ20 항체의 사용 방법
BRPI0515604A (pt) * 2004-09-08 2008-07-29 Genentech Inc método para o tratamento de células de cáncer e método de tratamento de uma doença imune relacionada
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2006210838B2 (en) 2005-02-02 2011-10-20 The Uab Research Foundation Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
US20090155247A1 (en) * 2005-02-18 2009-06-18 Ashkenazi Avi J Methods of Using Death Receptor Agonists and EGFR Inhibitors
US7629315B2 (en) * 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
WO2007094842A2 (en) 2005-12-02 2007-08-23 Genentech, Inc. Binding polypeptides and uses thereof
WO2007022157A2 (en) 2005-08-16 2007-02-22 Genentech, Inc. Apoptosis sensitivity to ap02l/trail by testing for 'galnac-t14 expression in cells/tissues
WO2007024921A2 (en) * 2005-08-24 2007-03-01 Cell Matrix Combination therapies for inhibiting integrin-extracellular matrix interactions
JP6088723B2 (ja) 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
US20070218504A1 (en) * 2006-03-09 2007-09-20 University Of Pittsburgh Human leptin-derived polypeptides and uses thereof
EP2379585A2 (en) 2008-10-10 2011-10-26 Anaphore, Inc. Polypeptides that bind trail-ri and trail-r2
CA2777162A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that bind il-23r
KR20120101050A (ko) 2009-11-05 2012-09-12 더 유에이비 리서치 파운데이션 기저형 유전자형 암의 치료 방법
WO2011116344A2 (en) 2010-03-18 2011-09-22 The Uab Research Foundation Targeting cancer stem cells
RS54846B1 (sr) 2010-10-29 2016-10-31 Daiichi Sankyo Co Ltd Novo anti-dr5 antitelo
CA2828405A1 (en) 2011-02-28 2012-09-07 Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Apoptosis-inducing molecules and uses therefor
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
CN102898526A (zh) * 2011-07-28 2013-01-30 山东先声麦得津生物制药有限公司 一种肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
DK2970473T3 (da) 2013-03-14 2017-11-27 Bristol Myers Squibb Co Kombination af dr5-agonist og anti-pd-1-antagonist og fremgangsmåder til anvendelse heraf
GB201312155D0 (en) 2013-07-05 2013-08-21 Ucl Business Plc Therapeutic invention
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EP3439687A1 (en) 2016-04-07 2019-02-13 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
EP3323428A1 (en) 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selective c-flip inhibitors as anticancer agents
EP3910331A1 (en) 2020-05-15 2021-11-17 iOmx Therapeutics AG Intracellular kinase associated with resistance against t-cell mediated cytotoxicity, and uses thereof
GB202016058D0 (en) 2020-10-09 2020-11-25 Ucl Business Ltd Therapeautic treatment
EP4257132A1 (en) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3 inhibitors for treating diseases resistant to death receptor signalling

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122408A0 (en) 1995-06-29 1998-06-15 Immunex Corp Dna encoding a trail polypeptide and its preparation
EP1862548A1 (en) 1997-01-28 2007-12-05 Human Genome Sciences, Inc. Death domain containing receptor 4 (DR4 : death receptor 4), member of the TNF-receptor superfamily and binding to trail (APO2-L)
US20010010924A1 (en) * 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
US6313269B1 (en) * 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
US6872568B1 (en) * 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
CA2644454A1 (en) * 1997-03-17 1998-09-24 Human Genome Sciences, Inc. Death domain containing receptor 5
EP1007562A4 (en) * 1997-04-16 2000-09-27 Millennium Pharm Inc TANGO-63d AND TANGO-63e PROTEINS RELATED TO THE TUMOR NECROSIS FACTOR RECEPTOR
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
EP0981618B2 (en) * 1997-05-15 2011-08-24 Genentech, Inc. Anti-apo-2 antibody
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
JP2001514888A (ja) 1997-08-15 2001-09-18 アイドゥン ファーマシューティカルズ， インコーポレイテッド Ｔｒａｉｌレセプター、これをコードする核酸、およびその使用方法
EP1012179A2 (en) 1997-09-12 2000-06-28 Apotech R&D S.A. Cysteine rich receptors: trail

Also Published As

Publication number Publication date
DE69832178T2 (de) 2006-07-20
EP1005488B9 (en) 2012-04-18
EP1005488B2 (en) 2011-12-14
CA2279838A1 (en) 1998-08-20
DK1005488T3 (da) 2006-03-06
US6072047A (en) 2000-06-06
AU735686B2 (en) 2001-07-12
ES2251767T5 (es) 2012-03-07
EP1676857A3 (en) 2007-04-04
IL131030A0 (en) 2001-01-28
EP1005488A4 (en) 2003-03-05
AU6650598A (en) 1998-09-08
EP1676857A2 (en) 2006-07-05
WO1998035986A1 (en) 1998-08-20
EP1005488A1 (en) 2000-06-07
JP5031132B2 (ja) 2012-09-19
DE69832178T3 (de) 2012-03-29
IL131030A (en) 2011-02-28
NZ336929A (en) 2000-11-24
DE69832178D1 (de) 2005-12-08
ES2251767T9 (es) 2012-10-17
EP1005488B1 (en) 2005-11-02
JP2002514069A (ja) 2002-05-14
HK1029796A1 (en) 2001-04-12
ATE308561T1 (de) 2005-11-15
ES2251767T3 (es) 2006-05-01
US6569642B1 (en) 2003-05-27
US6642358B1 (en) 2003-11-04

Similar Documents

Publication Publication Date Title
DK1005488T4 (da) Receptor som binder TRAIL
ATE353906T1 (de) Cd27 ligand
EP0871702A4 (en) CYTOKINE DESIGNED BY LERK-7
NZ504548A (en) Polypeptides and nucleic acids encoding human chordin
WO1998038212A3 (en) Chimeric polypeptides containing chemokine domains
NO960652L (no) Cytokiner som binder celleoverflatereseptoren hek
HK1144684A1 (en) Igf-1 fusion polypeptides and therapeutic uses thereof igf-1
HK1013847A1 (en) Gdf-1 and uog-1 proteins
DE69334100D1 (de) Elk ligand, ein cytokin
DE3585790D1 (de) Varicella-zoster-virus-dns-sequenzen, diese enthaltende vektoren und wirtzellen, uebereinstimmende polypeptide und diese enthaltende verbindungen.
WO1999003881A3 (fr) Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
BR9912455A (pt) ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória
MXPA00003885A (es) Quimiocinas con modificiaciones de la terminacion amino.
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
AU6292694A (en) Novel polypeptide, dna coding for said polypeptide, recombinant vector containing said dna, recombinant virus prepared using said vector, and use thereof
WO2002005843A3 (en) Human rrp sequences and methods of use
WO2000058465A3 (en) Flint polypeptide analogs
EP0879879A3 (en) Polypeptide deformylase 1 (Def1)
WO1997036919A3 (en) Cytokine designated lerk-8
WO2001070808A3 (en) Angiogenesis - associated proteins, and nucleic acids encoding the same
ATE304553T1 (de) Polypeptide mit wasserkanalaktivität und dna sequenzen
EE200100234A (et) PRV-1-geen ja selle kasutamine
EP0893501A3 (en) Ferrichrome transport atp-binding protein
WO2001042295A3 (en) Clasp-7 transmembrane protein
AU5990100A (en) ICBP90 polypeptide and its fragments and polynucleotides coding for said polypeptides and applications for diagnosing and treating cancer